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Summary
Background.  —  The  salt  linked  to  the  clopidogrel  molecule  in  generic  preparations  is  suspected
to affect  its  clinical  efﬁcacy.  There  is  a  lack  of  information  about  inhibition  of  platelet  reactivity
by generic  preparations.
Aims.  —  To  compare  the  effect  of  original  clopidogrel  (clopidogrel  bisulphate  [Plavix®]),  generic
clopidogrel  preparations  (clopidogrel  hydrochloride  [Clopidogrel-Mepha®];  clopidogrel  besylate
[Clopidogrel  Sandoz®])  and  prasugrel  (Eﬁent®)  on  platelet  reactivity  in  patients  with  coronary
artery disease.
Methods.  —  Patients  with  coronary  artery  disease  treated  with  stents  received,  in  a  random
sequence,  original  clopidogrel  bisulphate,  clopidogrel  hydrochloride  and  clopidogrel  besylate.
Platelet  function  was  assessed  with  the  Multiplate  analyser  after  an  initial  loading  dose  (600  mg)
and at  day  10  after  each  treatment  period.  Prasugrel  was  given  for  another  10  days.  An  adenosine
e  <  46  antiaggregation  units  (U)  was  deﬁned  as  therapeutic  plateletdiphosphate  (ADP)  test  valu
inhibition.
Results. —  Sixty  patients  (mean  age  69  ±  10  years;  50  men)  were  randomized.  Original  clopido-
grel bisulphate,  clopidogrel  hydrochloride  and  clopidogrel  besylate  provided  similar  inhibition
Abbreviations: ADP, adenosine diphosphate; PCI, percutaneous coronary intervention; U, antiaggregation units.
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of  platelet  reactivity  with  values  of  31  ±  25,  33  ±  28  and  28  ±  23  U,  respectively  (P  not  sig-
niﬁcant).  Prasugrel  provided  better  inhibition  of  platelet  function  (10  ±  11  vs.  31  ±  25  U  for
clopidogrel  bisulphate;  P  <  0.001).  An  ADP  test  value  >  46  U  was  measured  in  11  patients  (18%)
with clopidogrel  bisulphate,  13  (22%)  with  clopidogrel  besylate  and  13  (22%)  with  clopidogrel
hydrochloride  compared  with  only  one  (2%)  with  prasugrel.  Conclusion  Generic  clopidogrel
preparations  provided  similar  inhibition  of  platelet  reactivity  to  original  clopidogrel  bisulphate,
although prasugrel  was  more  efﬁcient.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Objectifs.  —  Le  but  de  cette  étude  est  de  comparer  l’effet  sur  l’agrégation  plaquettaire  de  la
molécule originale  de  clopidogrel  (clopidogrel  bisulfate  [Plavix®])  aux  molécules  génériques
(clopidogrel  besylate  [clopidogrel  Sandoz®]  et  clopidogrel  hydrochloride  [clopidogrel-Mepha®])
et au  prasugrel  (Eﬁent®).
Historique.  —  On  suspecte  que  le  sel  utilisé  pour  lier  la  molécule  de  clopidogrel  pourrait  changer
l’efﬁcacité  du  médicament  et  par  là  même  avoir  un  impact  sur  son  activité  d’antiagrégant
plaquettaires.  Aucune  information  n’est  actuellement  disponible.
Méthode.  —  Des  patients  avec  maladie  coronaire  traités  par  angioplastie  et  mise  en  place  de
stent ont  été  inclus  dans  cette  étude.  Ils  ont  rec¸u  de  manière  randomisée  les  trois  molécules  de
clopidogrel,  à  savoir  le  clopidogrel  bisulfate  (Plavix®),  le  clopidogrel  hydrochloride  (Clopidogrel-
Mepha®)  et  le  clopidogrel  besylate  (Clopidogrel  Sandoz®)  pour  une  durée  de  dix  jours  chacune.
Après cette  période  de  30  jours  les  malades  étaient  placés  sous  prasugrel  pour  une  nouvelle
période de  dix  jours.  L’agrégation  plaquettaire  a  été  mesurée  après  la  dose  de  charge  (600  mg)
et après  chaque  intervalle  de  traitement  de  dix  jours.  Un  appareil  de  type  Multiplate  Analyzer  a
été utilisé  pour  évaluer  la  fonction  plaquettaire.  Une  valeur  d’ADP  inférieure  à  46  U  représentait
une antiagrégation  plaquettaire  efﬁcace.
Résultats.  —  Soixante  patients  (50  hommes)  avec  un  âge  moyen  de  69  ±  10  ans  ont  été  inclus.  Il
n’y avait  pas  de  différence  signiﬁcative  de  l’activité  antiagrégante  entre  les  trois  préparations
de clopidogrel,  le  clopidogrel  bisulfate,  le  clopidogrel  hydrochloride  et  le  clopidogrel  besylate
avec des  valeurs  d’ADP  de,  respectivement,  31  ±  25  U,  33  ±  28  et  28  ±  23  U  (p  =  NS).  Le  prasugrel
est signiﬁcativement  plus  efﬁcace  que  l’ensemble  des  clopidogrel  ;  10  ±  11  U  vs.  31  ±  25  U.  Une
valeur d’ADP  supérieure  à  46  U  a  été  observée  chez  11  malades  avec  le  clopidogrel  bisulfate
(19,6 %),  12  malades  (21,1  %)  avec  le  clopidogrel  besylate  et  13  malades  (23,2  %)  avec  le  clopid-
ogrel hydrochloride.  Seul  un  patient  (2,3  %)  avec  le  prasugrel  avait  une  valeur  d’ADP  supérieure
à 46  U.
Conclusion.  — Le  niveau  d’antiagrégation  plaquettaire  obtenu  avec  les  préparations  génériques
de clopidogrel  est  comparable  à  celui  obtenu  avec  la  forme  originale  alors  que  le  prasugrel  est
plus efﬁcace.
©  2012  Elsevier  Masson  SAS.  Tou
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anaemia;  thrombocytopenia;  moderate-to-severe  renal  fail-ackground
ual  antiplatelet  therapy  with  aspirin  and  thienopyridine  is
ssential  after  coronary  intervention  and  stent  placement
1—3].  The  level  of  on-treatment  platelet  reactivity  is  asso-
iated  with  long-term  adverse  cardiovascular  events  after
ercutaneous  coronary  intervention  (PCI)  [4].  The  efﬁcacy
f  such  treatment  is  largely  inﬂuenced  by  interindividual
ariability  in  the  pharmacodynamic  response  to  clopidogrel
5,6].  In  addition,  clopidogrel  recently  became  generic;  sev-
ral  commercial  preparations  are  now  available  in  which
lopidogrel  is  linked  to  a  salt  that  might  change  its  clini-
al  efﬁcacy.  None  of  these  generic  preparations  has  been
alidated  other  then  by  pharmacodynamic  tests.  In  this
rospective  trial,  we  use  a  platelet  function  test  [7]  to  com-
are,  in  routine  clinical  practice,  platelet  reactivity  after
andomized  administration  of  two  new  generic  clopidogrel
reparations  (clopidogrel  besylate  [Clopidogrel  Sandoz®]
u
a
is  droits  réservés.
nd  clopidogrel  hydrochloride  [Clopidogrel-Mepha®])  and
he  original  preparation  (clopidogrel  bisulphate  [Plavix®]).
ethods
atient selection and study design
onsecutive  patients  with  ischaemic  heart  disease  under-
oing  PCI  with  stent  implantation  were  considered  for
nrolment  in  this  trial.  PCI  was  performed  using  standard
echniques  by  the  femoral  or  radial  route.  Exclusion  crite-
ia  were:  cardiogenic  shock;  pregnancy;  intolerance  to
spirin,  thienopyridine  or  contrast  media;  poor  compli-
nce;  active  bleeding;  inability  to  give  informed  consent;re  (deﬁned  as  creatinine  clearance  of  30  to  60  mL/min
nd  <  30  mL/min,  respectively);  planned  surgery;  or  inabil-
ty  to  have  follow-up  information.  Patients  already  treated
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oFigure 1. Trial design. ADP: adenosine diphosphate; PCI: percuta
with  thienopyridines  were  equally  excluded.  All  patients
gave  their  written  informed  consent  and  the  protocol  was
approved  by  the  hospital’s  ethical  committee.  The  con-
trol  group  was  composed  of  50  healthy  medication-free
adults.  The  subjects  in  the  control  group  did  not  receive  any
antiplatelet  therapy.  The  rationale  behind  having  a  control
group  was  to  conﬁrm  the  validity  of  the  platelet  aggregation
test.
This  was  a  single-blind  randomized  trial  with  complete
crossover  (Fig.  1).  The  primary  endpoint  was  therapeutic
antiaggregation  deﬁned  as  a  value  of  <  46  antiaggregation
units  (U)  on  whole  blood  platelet  function  testing.  Random-
ization  was  achieved  with  envelopes,  the  patients  being
assigned  to  one  of  the  three  clopidogrel  groups  for  10  days,
then  crossed  over  to  another  clopidogrel  molecule,  as  shown
in  Fig.  1.
Percutaneous coronary intervention and
antiplatelet therapy management
At  the  time  of  PCI,  all  patients  received  500  mg  of  aspirin  in
addition  to  either  unfractionated  or  low-molecular-weight
heparin.  A  loading  dose  (600  mg)  of  clopidogrel  was  given
at  the  end  of  the  procedure.  The  clopidogrel  molecule
was  chosen  at  random  between  original  clopidogrel  bisul-
phate,  clopidogrel  hydrochloride  or  clopidogrel  besylate.
After  treatment  initiation,  the  clopidogrel  preparation  was
given  for  10  days  at  a  dose  of  75  mg/day.  At  days  10  and  20,
the  clopidogrel  molecule  was  changed  to  a  new  molecule,  so
that  after  30  days  all  patients  had  received  all  clopidogrel
preparations  for  10  days.  After  this  initial  30-day  period,
a  loading  dose  (60  mg)  of  prasugrel  was  given,  followed  by
a  maintenance  dose  of  10  mg/day  for  10  days.  After  these
40  days,  the  patient  was  left  for  1  year  on  the  drug  that
provided  the  lowest  platelet  reactivity.
a
d
(s coronary intervention.
latelet reactivity assessment
latelet  reactivity  testing  of  clopidogrel  and  prasugrel  was
erformed  using  the  Multiplate  analyser  (Dynabyte,  Munich,
ermany).  This  method  has  been  approved  for  human  use
y  the  United  States  Food  and  Drug  Administration.  The
ssay  is  made  up  of  two  distinct  silver  electrode  sensors.
he  changes  in  the  electrodes’  impedance  after  platelet
dhesion  is  detected  by  the  sensor  and  allows  aggregation
nits  to  be  calculated.  The  variables  evaluated  are:  maxi-
al  aggregation,  velocity  (steepness  of  the  curve)  and  area
nder  the  curve  (AUC,  AU  min),  calculated  from  the  mean
alues  of  the  two  curves.  The  ﬁnal  result  is  expressed  in
nits  (U),  with  1  U  deﬁned  as  10  AU  min.  Platelet  reactivity
as  assessed  6  hours  after  the  loading  dose  of  clopidogrel
nd  every  10  days  at  the  time  of  the  switch  of  the  clopido-
rel  preparation.  Efﬁcient  platelet  inhibition  was  deﬁned  as
n  adenosine  diphosphate  (ADP)  test  value  <  46  U.  Patients
ith  values  >  46  U  received  a  loading  dose  of  another  clopid-
grel  preparation  on  the  same  day,  with  repeated  platelet
unction  measurement  after  6  hours.
For  the  trial,  the  operator  determining  platelet  reactivity
as  blinded  to  the  treatment  arm,  patient  characteristics
nd  biomarkers.
tatistical analyses
e  performed  a  power  analysis  that  concluded  the  inclu-
ion  of  60  patients  at  resistance  rates  of  15%  for  original
lopidogrel  and  40%  for  the  generic  clopidogrel  preparations
ould  yield  a  statistical  power  of  88%  at  a  signiﬁcance  level
f  alpha  equal  to  0.05  for  a  two-tailed  analysis.  The  power
nalysis  was  performed  for  proportions  of  paired  samples.
Continuous  variables  are  presented  as  mean  ±  standard
eviation  and  after  conﬁrmation  of  a  normal  distribution
QQ  plot).  To  compare  antiaggregation  units  achieved  with
590  M.  Oberhänsli  et  al.
Table  1  Patient  characteristics.
Study  cohort  Control  group
(n  =  60)  (n  =  50)
Men 50  (83)  12  (24)
Age  (years)  68  ±  9  39  ±  10
Body  mass  index  (kg/m2)  27  ±  5  22  ±  4
Diabetes  20  (33)  0
Hypertension 18  (30)  2  (4)
Current  smoker 14  (23) 14  (28)
Former  smoker 24  (40) 3  (6)
Dyslipidaemia 42  (70) 5  (10)
Family  history 22  (37) 13  (26)
Renal  failure  4  (7)  0
Heart  failure 6  (10)  0
STEMI  0  0
Acute  coronary  syndrome 17  (28) 0
Stable  angina 28  (47) 0
Silent  ischaemia 15  (25) 0
Data are mean ± standard deviation or number (%). STEMI:
ST-segment elevation myocardial infarction.
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Figure 2. Distribution of platelet reactivity after loading dose.
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sis.  Thus,  as  clopidogrel  has  become  generic,  with  severalhe  different  clopidogrel  preparations,  the  paired  t  test  was
mployed.  Categorical  variables  are  presented  as  numbers
nd  percentages.  We  considered  a  P  value  <  0.05  as  signiﬁ-
ant.  SPSS  software,  version  18  (SPSS  Inc.,  Chicago,  IL,  USA)
as  used  for  statistical  analyses.
esults
ixty  patients  (50  men  and  10  women)  with  a  mean  age  of
9  ±  10  years  were  included.  The  control  group  was  com-
osed  of  50  healthy  adults  (22%  men)  who  were  not  taking
ny  medication  and  had  a  mean  age  of  39  ±  10  years.
Patient  characteristics  are  shown  in  Table  1.  Brieﬂy,  the
atients  had  the  usual  risk  factors  expected  in  patients  with
schaemic  heart  disease.  Baseline  coagulation  variables  and
latelet  reactivity  were  normal  for  all  patients  (platelet
ount  225  ±  57  g/L,  prothrombin  time  92  ±  13%,  activated
artial  thromboplastin  time  33  ±  4  seconds).
After  the  loading  dose,  platelet  reactivity  was  the
ame  for  all  clopidogrel  preparations,  with  a  mean  value
f  17  ±  15  U  for  clopidogrel  bisulphate,  23  ±  16  U  for
lopidogrel  hydrochloride  and  21  ±  16  U  for  clopidogrel  besy-
ate  (P  =  0.43;  Fig.  2).  After  10  days  of  treatment,  there
ere  no  signiﬁcant  differences  between  the  clopidogrel
reparations,  with  a  mean  value  of  31  ±  25  U  for  clopid-
grel  bisulphate,  33  ±  28  U  for  clopidogrel  hydrochloride
nd  28  ±  23  U  for  clopidogrel  besylate  (P  =  0.69;  Table  2;
ig.  3).  There  were  no  statistical  differences  between
he  groups:  clopidogrel  bisulphate  vs.  clopidogrel  besylate
P  =  0.58);  clopidogrel  bisulphate  vs.  clopidogrel  hydrochlo-
ide  (P  =  0.34);  and  clopidogrel  hydrochloride  vs.  clopidogrel
esylate  (P  =  0.14)  (Fig.  3).  For  all  clopidogrel  preparations,
he  higher  platelet  reactivity  inhibition  was  obtained  after
he  loading  dose,  as  shown  in  Table  2.  Eleven  (18%)  patients
howed  values  >  46  U  for  clopidogrel  bisulphate,  13  patients
c
i
rigure 3. Distribution of platelet reactivity after 10 days of treat-
ent.
22%)  for  clopidogrel  hydrochloride  and  13  patients  (22%)  for
lopidogrel  besylate  (Table  2).
Prasugrel  was  signiﬁcantly  more  efﬁcient  than  any  prepa-
ation  of  clopidogrel,  with  a  mean  value  of  10  ±  11  U
P  <  0.001);  only  one  patient  (2%)  exhibited  a value  >  46  U.
iscussion
tent  thrombosis  remains  a  partially  unsolved  problem,
ssociated  with  a  high  rate  of  morbidity  and  mortality
fter  PCI.  A  signiﬁcantly  higher  rate  of  stent  thrombosis  in
atients  with  higher  on-treatment  platelet  reactivity  has
een  reported,  with  an  incidence  of  up  to  3%  [8].  Also,
sing  the  P2Y12  point-of-care  assay,  high  platelet  reactiv-
ty  (P2Y12  reactivity  units  >  230)  was  associated  with  higher
ates  of  death,  myocardial  infarction  or  stent  thrombo-ommercial  preparations  now  available,  it  is  of  critical
mportance  to  demonstrate  that  similar  inhibition  of  platelet
eactivity  can  be  achieved  with  these  preparations.
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Table  2  Mean  antiaggregation  values  for  the  treated  population  and  controls  (adenosine  diphosphate  test).
n Mean  U  ±  standard  deviation  %  of  patients  with
ADP  test  value  <  46  U
No  treatment  Loading  dose  Maintenance  dose
Clopidogrel  bisulphate
(Plavix®)
60 17  ±  15  31  ±  25  82
Clopidogrel  besylate
(Clopidogrel
Sandoz®)
60 21 ± 16  28 ±  23  78
Clopidogrel
hydrochloride
(Clopidogrel-Mepha®)
60  23  ±  16  33  ±  28  78
Prasugrel  (Eﬁent®)  60  6  ±  16  10  ±  11  98
Control  group  (no
treatment)
50  61  ±  17
ADP: adenosine diphosphate; U: antiaggregation units.
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of  clopidogrel  tested  provide  similar  inhibition  of  platelet
reactivity  and  that  generic  preparations  can  be  used  safely
after  PCI.  We  found  36  patients  (21.9%)  taking  any  clopid-
ogrel  who  had  an  ADP  test  value  >  46  U;  they  have  to  be
considered  as  clopidogrel  resistant.  This  is  in  line  with  pre-
vious  reports  showing  clopidogrel  resistance  in  23  to  40%  of
patients  [9].  Our  results  show  a  wide  response  variability;
thus  a  clear  cut-off  value  to  deﬁne  true  clopidogrel  resis-
tance  has  still  to  be  determined,  as  in  other  reported  trials
[10].  Furthermore,  platelet  reactivity  is  not  the  only  vari-
able  involved  in  stent  thrombosis-implantation  technique,
angiographic  result  and  clinical  status  (such  as  acute  coro-
nary  syndrome  or  comorbidities  such  as  diabetes)  also  affect
the  rate  of  stent  thrombosis  and  morbidity  [11].
It  has  also  been  recently  shown  that  the  incidence  of
major  adverse  clinical  events,  including  stent  thrombosis,
is  higher  when  platelet  reactivity  is  still  present  at  a  high
value  (>  46  U)  when  the  Multiplate  analyser  is  used  [4,8].
Our  data  conﬁrm  the  results  of  two  previous  trials
comparing  original  clopidogrel  with  generic  clopidogrel
preparations  in  healthy  subjects  [12,13].  These  trials
showed  similar  safety  proﬁles  and  met  the  criteria  for  phar-
macokinetic  bioequivalence.  Only  healthy  volunteers  were
included  in  these  studies,  which  is  a  limitation  because
patients  with  atherosclerotic  disease  have  a  higher  degree  of
variability  in  their  response  to  clopidogrel  due  to  comorbidi-
ties  and  multiple  comedications.  Our  trial,  by  comparison,
was  conducted  in  a  real-life  setting,  with  patients  who  had
a  clinical  indication  for  antiplatelet  therapy.
In  addition,  our  data  conﬁrm  the  value  of  prasugrel
as  a  potent  antiplatelet  agent.  Prasugrel,  like  clopidogrel,
requires  conversion  to  an  active  metabolite  before  bind-
ing  to  the  platelet  P2Y12  receptor  to  confer  antiplatelet
activity.  Prasugrel  inhibits  ADP-induced  platelet  aggregation
more  rapidly,  more  consistently  and  to  a  greater  extent
than  standard  and  higher  doses  of  clopidogrel  in  healthy
volunteers  and  in  patients  with  coronary  artery  disease
undergoing  PCI  [14—16]. When  antiaggregation  is  of  criti-
cal  importance  (patients  with  multiple  stenting,  multivesselisease  or  left  main  PCI,  diabetic  patients,  etc.),  clopidogrel
esistance  can  be  avoided  with  prescription  of  prasugrel,
long  with  very  efﬁcient  inhibition  of  platelet  reactivity.
tudy limitations
he  main  limitation  of  this  trial  was  the  small  number
f  patients.  However,  it  seems  obvious  that  a  signiﬁcant
ifference  between  the  original  and  generic  clopidogrel
reparations  would  require  a  considerable  number  of
atients  to  show  very  little  difference.  Moreover,  any  bene-
t  favouring  one  of  the  preparations  would  not  necessarily
e  correlated  with  better  clinical  outcome.  As  the  platelet
eactivity  test  has  limitations,  its  routine  use  in  clinics  also
as  limitations  and  results  should  be  interpreted  in  the  set-
ing  of  the  clinical  situation.  Finally,  there  are  no  large-scale
rials  that  show  clinical  outcome  improvement  after  adap-
ation  of  antiplatelet  therapy  using  the  platelet  reactivity
est  [8].
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